ABBV-154

• UNSPSC Description:

  ABBV-154 is an anti-TNF antibody-drug conjugate (ADC). ABBV-154 is composed of the humanized antibody Adalimumab (HY-P9908) conjugated with a glucocorticoid receptor modulator (HY-137883). ABBV-154 can be used in studies of rheumatoid arthritis, Crohn's disease and polymyalgia rheumatica[1].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); Glucocorticoid Receptor; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Apoptosis;Immunology/Inflammation;Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/abbv-154.html

• Smiles:

  [ABBV-154]

• References & Citations:

  [1]Hobson AD, et al. Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC). J Med Chem. 2023 Sep 14;66(17):12544-12558.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2